Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.68 |
| ▸ | ATRIP | Q8WXE1 | 20/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
| ▸ | PRKDC | P78527 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25080690 | 1.00 | ATR (0.68) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL25790786 | 0.89 | ATR (0.64) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL25080340 | 0.89 | ATR (0.64) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL25790818 | 0.89 | ATR (0.64) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL25080348 | 0.87 | ATR (0.66) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL30443518 | 0.86 | ATR (0.53) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL31362629 | 0.86 | ATR (0.53) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL25293810 | 0.86 | ATR (0.53) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL25288070 | 0.84 | ATR (0.52) | ATRATRIPLCKMTORNUAK1 | |
| SCHEMBL30443476 | 0.84 | ATR (0.52) | ATRATRIPLCKMTORNUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435095-B2 | Substituted morpholines as ATR kinase inhibitors | SHANGHAI ANNOVA BIOTECHNOLOGY CO., LTD. (CN) | 2025-10-07 | — | — | US | disclosed |
| CN-116761804-B | Substituted condensed heterocyclic compound, preparation method and application thereof | 上海安诺达生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250051362-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI ANNOVA BIOTECHNOLOGY CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4455144-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Annova Biotechnology Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| CN-116761804-A | Substituted condensed heterocyclic compound, preparation method and application thereof | 上海安诺达生物科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| WO-2023116594-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海安诺达生物科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-116283960-A | Substituted condensed heterocyclic compound, preparation method and application thereof | 上海安诺达生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023020604-A1 | FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLIC AND HETEROARYL DERIVATIVE AND USE THEREOF | 南京大美生物制药有限公司 | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435095-B2 | Substituted morpholines as ATR kinase inhibitors | ATR, WEE1, WEE2 | ATR 1/4885ATRIP 7/4885LCK 387/4885 |
| US-20250051362-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, ATR, WEE2 | ATR 2/4885ATRIP 9/4885LCK 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.